0JBU.LSE Intellia Therapeutics, Inc.
- Market cap
- -
- P/E
- -
- P/B
- -
- ROE
- -55.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 0JBU.LSE undervalued?
Graham numberThe Graham number of Intellia Therapeutics, Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Intellia Therapeutics, Inc. fundamental analysis
No fundamental analysis for Intellia Therapeutics, Inc. yet.
Intellia Therapeutics, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Intellia Therapeutics, Inc.
Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeats ("CRISPR")/CRISPR associated 9 ("Cas9") technology for genome editing. The company provides a modular platform, to advance in vivo and ex vivo therapies for diseases. The company's in vivo product candidates include nexiguran z…
Full company profileIntellia Therapeutics, Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Intellia Therapeutics, Inc. annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 16.5M | 26.1M | 30.4M | 43.1M | 58.0M | 33.1M | 52.1M | 36.3M | 57.9M | 67.7M | 45.4M |
| Gross Profit | -15.4M | -41.5M | -58.7M | -65.3M | -92.4M | 26.2M | 44.5M | -399M | 47.6M | 51.7M | 36.8M |
| Operating Income | -32.2M | -69.6M | -90.9M | -106M | -137M | -268M | -458M | -515M | -534M | -441M | -427M |
| EBITDA | -31.1M | -66.6M | -86.4M | -101M | -128M | -261M | -451M | -506M | -509M | -425M | -418M |
| Net Income | -31.6M | -67.5M | -85.3M | -99.5M | -134M | -268M | -474M | -481M | -519M | -413M | -406M |
| EPS | -1.42 | -1.88 | -1.98 | -2.11 | -2.40 | -3.78 | -6.16 | -5.42 | -5.25 | -3.81 | -3.04 |
| Balance Sheet | |||||||||||
| Total Assets | 299M | 376M | 347M | 334M | 676M | 1.29B | 1.52B | 1.30B | 1.19B | 842M | 857M |
| Total Liabilities | 89.1M | 75.6M | 69.4M | 64.4M | 149M | 254M | 285M | 251M | 319M | 171M | 129M |
| Shareholders' Equity | 210M | 301M | 278M | 270M | 527M | 1.04B | 1.24B | 1.05B | 872M | 671M | 728M |
| Cash & Short-term Investments | 273M | 341M | 314M | 280M | 600M | 749M | 1.19B | 912M | 602M | 450M | 438M |
| Total Debt | - | - | - | 12.6M | 39.3M | 74.0M | 131M | 115M | 210M | 160M | 73.4M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 36.1M | -65.3M | -61.3M | -103M | -49.9M | -225M | -333M | -394M | -349M | -395M | -401M |
| Capital Expenditure | 6.17M | 10.1M | 6.36M | 6.79M | 3.59M | 12.8M | 13.6M | 14.0M | 5.78M | 1.13M | 3.78M |
| Free Cash Flow | 29.9M | -75.4M | -67.6M | -110M | -53.5M | -238M | -347M | -408M | -355M | -396M | -405M |
| Ratios | |||||||||||
| ROE | -15.1% | -22.5% | -30.7% | -36.9% | -25.5% | -25.8% | -38.4% | -45.8% | -59.5% | -61.5% | -55.8% |
| ROA | -10.6% | -18.0% | -24.6% | -29.8% | -19.8% | -20.7% | -31.2% | -37.0% | -43.6% | -49.0% | -47.3% |
| Net Profit Margin | -192.0% | -258.6% | -280.4% | -230.9% | -231.5% | -810.5% | -909.8% | -1,326.5% | -896.8% | -609.9% | -893.4% |
| Debt to Equity | - | - | - | 0.05x | 0.07x | 0.07x | 0.11x | 0.11x | 0.24x | 0.24x | 0.10x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Intellia Therapeutics, Inc. dividends
Intellia Therapeutics, Inc. has not paid dividends in the last 9 fiscal years.
Who owns Intellia Therapeutics, Inc.
- Insiders 3.84%
- Institutions 96.16%
- Public & others 0.00%
- Free float 134M
Intellia Therapeutics, Inc. company profile
- Company name
- Intellia Therapeutics, Inc.
- Ticker
- 0JBU.LSE
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 377
- Fiscal year end
- December
- Address
- 400 Technology Square, Cambridge, MA, United States, 02139
- Phone
- (857) 285-6200
- Website
- intelliatx.com
About Intellia Therapeutics, Inc.
Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeats ("CRISPR")/CRISPR associated 9 ("Cas9") technology for genome editing. The company provides a modular platform, to advance in vivo and ex vivo therapies for diseases. The company's in vivo product candidates include nexiguran ziclumeran, or NTLA-2001 for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema. Additionally, it offers product candidates for the treatment of immuno-oncology and autoimmune diseases, and multiple in vivo programs to address diseases with significant unmet medical need by delivering gene editing therapeutics to organs outside the liver. The company has license and collaboration agreement with AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of various of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer; and ReCode Therapeutics, Inc. to develop novel genomic medicines for the treatment of cystic fibrosis. It also has collaboration agreements with Regeneron Pharmaceuticals, Inc., SparingVision SAS, and Rewrite Therapeutics Inc. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Intellia Therapeutics, Inc. management
10- Dr. John M. Leonard M.D.President, CEO & Director · born 1957
- Mr. Edward J. Dulac IIIExecutive VP, CFO & Treasurer · born 1975
- Dr. Birgit Schultes Ph.D.Executive VP & Chief Scientific Officer · born 1963
- Mr. James E. Basta Esq., J.D.Executive VP, General Counsel & Corporate Secretary · born 1966
- Dr. Rachel E. Haurwitz Ph.D.Co-Founder · born 1986
- Dr. Jennifer A. Doudna Ph.D.Founder & Member of Scientific Advisor Board · born 1964
- Dr. Derrick J. Rossi Ph.D.Founder & Member of Scientific Advisor Board
- Dr. Rodolphe Barrangou M.B.A., Ph.D.Founder & Member of Scientific Advisor Board
- Prof. Luciano Marraffini Ph.D.Founder & Member of Scientific Advisor Board
- Mr. Erik J. Sontheimer Ph.D.Founder & Member of Scientific Advisor Board